Skip to main navigation Skip to search Skip to main content

The Impacts of 1115 Medicaid Substance Use Disorder Waivers on Medicaid-Paid Use of Residential Treatment and Other Types of Services in 20 States

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To assess the association between the implementation of 1115 Medicaid substance use disorder (SUD) waivers and changes in Medicaid-paid use of residential treatment and other types of services. Study Setting and Design: We compared 20 states with SUD waivers to 14 non-waiver states using a staggered difference-in-differences design. Primary outcomes were Medicaid-paid opioid-use disorder (OUD) related residential treatment stays and length of stay (LOS). Secondary outcomes included admissions and LOS for all-cause and OUD-related inpatient stays, psychiatric hospital admissions, emergency department (ED) visits, outpatient visits, and primary care visits. Data Source and Analytic Sample: We used the 2016–2021 Transformed Medicaid Statistical Information System (T-MSIS) Analytic Files (TAF). The analytic sample included Medicaid enrollees ages 18–64 with OUD. Principal Findings: On average, waiver implementation was associated with an increase in residential treatment stays (estimate: 0.4%; 95% CI: 0.1%–0.7%), OUD-related inpatient visits LOS (estimate: 0.3 days; 95% CI: 0.0%–0.5%), psychiatric hospital LOS (estimate: 1.0 days; 95% CI: 0.6 days–1.4 days), primary care visits (estimate: 3.0%; 95% CI: 1.2%–4.7%), and OUD-related primary care visits (estimate: 2.7%; 95% CI: 0.9%–4.4%); and a decline in all-cause inpatient visits (estimate: −0.9%; 95% CI: −1.9% to −0.0%) and OUD-related inpatient visits (estimate: −0.8%; 95% CI: −1.6% to −0.0%). Results for psychiatric hospital LOS and OUD-related primary care visits were sensitive to adjusting for pre-trends. Among four early-adopting states (Indiana, Louisiana, New Jersey, Virginia), Medicaid-paid residential treatment increased 1–4 years following waiver implementation (e.g., 2-year estimate: 2.8%, 95% CI: 2.5%–3.0%), and inpatient visits declined 1–4 years following waiver implementation (e.g., 2-year estimate: −3.1%, 95% CI: −3.5% to −2.6%). Conclusions: SUD waivers were associated with a small increase in Medicaid-paid residential treatment and a decline in inpatient visits across states, with changes being concentrated among early-adopting states.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalHealth Services Research
Volume61
Issue number1
DOIs
StatePublished - Feb 1 2026

Keywords

  • Medicaid
  • opioid use disorder
  • residential treatment
  • substance use disorder

ASJC Scopus subject areas

  • Health Policy

Fingerprint

Dive into the research topics of 'The Impacts of 1115 Medicaid Substance Use Disorder Waivers on Medicaid-Paid Use of Residential Treatment and Other Types of Services in 20 States'. Together they form a unique fingerprint.

Cite this